← AMN Healthcare Services overview

AMN Healthcare Services vs Option Care Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

AMN Healthcare Services Inc (AMN)

Q3 2026
▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

  • AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.

    New partnership expands AMN's AI-driven offerings, a key growth driver.

  • Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.

    Core staffing demand rebound is the main force behind AMN's improving results.

  • Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.

    Profit swing and upbeat guidance directly lift earnings expectations and stock price.

  • Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.

    Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.

August 2026
▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

  • AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.

    New partnership expands AMN's AI-driven offerings, a key growth driver.

  • Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.

    Core staffing demand rebound is the main force behind AMN's improving results.

  • Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.

    Profit swing and upbeat guidance directly lift earnings expectations and stock price.

  • Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.

    Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.

Latest
▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

  • AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.

    New partnership expands AMN's AI-driven offerings, a key growth driver.

  • Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.

    Core staffing demand rebound is the main force behind AMN's improving results.

  • Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.

    Profit swing and upbeat guidance directly lift earnings expectations and stock price.

  • Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.

    Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.

Option Care Health Inc (OPCH)

Q3 2026
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.

August 2026
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.

Latest
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.